Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure
Hypertension
About this trial
This is an interventional treatment trial for Hypertension focused on measuring Epicatechin, Polyphenols, Chocolate, Insulin Resistance, Endothelial Dysfunction, Hypertension
Eligibility Criteria
INCLUSION CRITERIA Hypertensive subjects between the ages of 21 - 65 years in good general health except for mild to moderate hypertension (blood pressure between 140/95 and 170/110 off medication), on no medication or nutritional supplements except for antihypertensive agents, anti-cholesterol drugs or birth control agents. Subjects will be taken off all antihypertensive OTC supplements and anti-cholesterol drugs for one week prior to study and for the duration of the study. Women on birth control will remain on their regime. During the time subjects receive no antihypertensive therapy, their blood pressure will be monitored at least daily (either at home, in the clinic, or at another convenient facility). If a subject's blood pressure exceeds 170/110 on three determinations over a period of at least 15 minutes, the subject will be withdrawn from the study and appropriate antihypertensive therapy resumed. In addition, if the subject's blood pressure exceeds 160/100 during measurements on three consecutive days, the subject will be withdrawn from the study and appropriate antihypertensive therapy resumed. EXCLUSION CRITERIA Subjects will be excluded if they have diabetes, pregnancy, liver disease, pulmonary disease, renal insufficiency, coronary heart disease, heart failure, peripheral vascular disease, coagulopathy, actively smoked tobacco within last two years, in treatment for any form of cancer, positive tests for HIV, hepatitis B or C, or take systemic corticosteroids. These conditions are all known to adversely influence insulin sensitivity. Subjects will be excluded if they have a history of malignant hypertension, aortic aneurysm or stroke. Subjects with known hypersensitivity to octafluoropropane or with known cardiac shunts will also be excluded from participating because of potential adverse effects from microbubble contrast agent. Subjects will be excluded if they are unable to give informed consent for all procedures. Children are excluded from this study because children are not typically hypertensive.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike